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Abstract
Background: Emerging evidence suggests that microRNAs play a critical role in the pathogenesis of breast cancer. Several
molecular epidemiological studies were conducted in recent years to evaluate the association between has-miR-146a
rs2910164 polymorphism and breast cancer risk in diverse populations. However, the results remain conflicting rather than
conclusive.
Methodology/Principal findings: We performed a meta-analysis of 6 case-control studies that included 4238 breast-cancer
cases and 4469 case-free controls. We assessed the strength of the association, using odds ratios (ORs) with 95% confidence
intervals (CIs). Overall, this meta-analysis showed that the rs2910164 polymorphism was not associated with a significantly
increased risk of breast cancer in all genetic models (for GC vs GG: OR=1.00, 95% CI=0.9021.09, Pheterpgeneity=0.364; for CC
vs GG: OR=1.16, 95% CI=0.9821.36, Pheterpgeneity=0.757; for GC+CC vs GG: OR=1.02, 95% CI=0.9321.12,
Pheterpgeneity=0.562; for CC vs GC+GG: OR=1.10, 95% CI=0.9621.26, Pheterpgeneity=0.441). However, in the stratified
analysis by ethnicity, we found the rs2910164 polymorphism was associated with increased breast cancer risk among
Europeans in homozygote comparison (CC vs. GG: OR=1.29, 95%CI=1.0221.63, Pheterpgeneity=0.950, P=0.032) and
recessive model (CC vs. GC+GG: OR=1.31, 95%CI=1.0521.65, Pheterpgeneity=0.839, P=0.019). No publication bias was found
in the present study.
Conclusions/Significance: This meta-analysis suggests, for the first time, that the CC homozygote of rs2910164 may
contribute to breast cancer susceptibility in Europeans.
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Introduction
Breast cancer (BC) is the most frequently diagnosed cancer and
the leading cause of cancer death among women globally. About
1.3 million women are diagnosed with BC annually worldwide and
about 465,000 die from the disease [1,2,3]. In the United States
BC is the second most common cause of cancer death in women
[1,3]. Moreover, BC incidence rates have been reported to
increase by up to 5% per year in developing countries [2,3,4].
Although environmental factors and lifestyle could contribute to
the increased BC risk, genetic factors are also implicated in the
pathogenesis of the disease. A current priority in BC research is to
identify genetic alterations that are directly involved in breast
carcinogenesis. To date, a great number of genetic variants have
been identified to be potentially associated with BC risk [5,6,7,8].
However, the molecular mechanisms that contribute to breast
carcinogenesis remain poorly understood.
Emerging evidence supports a role for microRNAs (miRNAs) in
BC development and progression [9,10]. miRNAs are non-coding,
single-stranded RNAs of ,22 nucleotides and constitute a novel
class of gene regulators that are found in both plants and animals.
miRNAs are predicted to target over 50% of all human protein-
coding genes, thus playing regulatory roles in a variety of
physiological and developmental processes [11,12]. Recent
evidence has shown that miRNA mutations or mis-expression
are correlated with various human cancers including BC [13,14].
For example, microRNA-146a has been shown to bind to the
39UTR of the BC susceptibility gene BRCA1 and negatively
regulate its expression [15,16]. A G.C polymorphism
(rs2910164), which is located in the sequence of miR-146a
precursor, results in a change from G:U to C:U in its stem region
[16]. Up to now, a few molecular epidemiological studies have
investigated the association between the miR-146a rs2910164
polymorphism and BC risk [16,17,18,19,20,21]. However, the
results remain controversial and ambiguous. Because a single study
might have been underpowered to detect the overall effects, a
quantitative synthesis of the accumulated data from different
studies is important to provide evidence on the association of
rs2910164 polymorphism with BC risk. Thus, in this study we
conducted a meta-analysis to combine all studies available and
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31615validate whether the miR-146a G.C polymorphisms contribute to
BC susceptibility.
Materials and Methods
Publication search
We searched the PubMed and Embase databases for all articles
on the association between has-miR146a rs2910164 polymorphism
and BC risk up to September 2011. The following key words were
used: ‘‘miR-146a/rs2910164,’’ ‘‘breast cancer/carcinoma,’’ and
‘‘polymorphism/variant’’. The electronic searching was supple-
mented by checking reference lists from the identified articles and
reviews for additional original reports. All the studies must meet
the following criteria: (1) case-control study; (2) the outcome had to
be breast cancer; and (3) at least two comparison groups (cancer
group vs. control group). The major exclusion criteria were: (1)
duplicate data, (2) abstract, comment, review and editorial, and (3)
no sufficient data were reported.
Data extraction
Two of the authors (H.L. and L.W.) extracted all data indepen-
dently,complied with the selectioncriteria,andreacheda consensus
on all items. In case of disagreement, a third author (JM.Z.) assessed
the articles. The following items were collected: first author’s name,
year of publication, country of origin, ethnicity, definition of study
patients (cases), genotyping method, total number of cases and
controls, and genotype distributions in cases and controls. PRISMA
Checklist for the studies was shown as Checklist S1.
Statistical analysis
The departure of frequencies of hsa-miR-146a polymorphism
from expectation under Hardy-Weinberg equilibrium (HWE) was
assessed by the chi-square test in controls and a P,0.05 was
considered as significant disequilibrium. The strength of the
association between the hsa-miR-146a polymorphism and BC risk
was measured by odds ratios (ORs) with 95% confidence intervals
(CIs). The significance of the pooled OR was determined by the Z-
test, and P,0.05 was considered statistically significant. For miR-
146a G/C, the meta-analysis examined the association between C
allele and BC risk compared with that for G allele in the co-
dominant model (GC versus GG, CC versus GG), dominant model
(GC/CC versus GG) and recessive model (CC versus GC/GG).
The heterogeneity among the studies was checked by using the chi-
square based Q statistic and considered statistically significant at
P,0.10 [22]. When P.0.10, the pooled OR of each study was
calculated by using the fixed-effects model (the Mantel-Haenszel
method, which weights the studies by the inverse of the variance of
estimates) [23]; otherwise, the random-effects model (the DerSimo-
nian and Laird method) [24] was used. To adjust for multiple
comparisons, we applied step-down Bonferroni method [25], which
control for familywise error rate (FWE). The significance threshold
was selected to be 0.1 after the Bonferroni correction, as used in the
previous studies [26,27]. The Begg’s rank correlation method and
the Egger’s weighted regression method were used to statistically
assess publication bias (P,0.05 was considered representative of
statistically significant publication bias) [28]. All analyses were done
using STATA software, version 11.0 (STATA Corp., College
Station, TX, USA), and all tests were two-sided.
Results
Characteristics of the studies
A total of 41 articles were achieved by literature search from the
PubMed and EMBASE, using different combinations of key terms.
As shown in Figure 1, 10 eligible studies were retrieved for detailed
evaluation. We excluded six studies (four not focused on
rs2910164, one was case only study and one did not present
usable data). One study identified by manually searching reference
lists of retrieved studies was also included [17]. Finally, a total of 6
case-control studies in 5 articles met our inclusion criteria
[17,18,19,20,21], including 4238 cases and 4469 controls.
Table 1 lists the characteristics of each study. There were four
studies of Europeans, one study of Asians and one study of mixed
populations. Genotyping methods included PCR-RFLP, TaqMan,
MassARRAY and PCR-direct sequencing. The genotype distri-
butions in the controls of all studies were in agreement with
Hardy-Weinberg equilibrium except for one study [20].
Quantitative synthesis
The results of the overall meta-analysis did not suggest any
associations between rs2910164 polymorphism and BC suscepti-
bility for all genetic models (for GC vs GG: OR=1.00, 95%
CI=0.9021.09, Pheterpgeneity=0.364; for CC vs GG: OR=1.16,
95% CI=0.9821.36, Pheterpgeneity=0.757; for GC+CC vs GG:
OR=1.02, 95% CI=0.9321.12, Pheterpgeneity=0.562; for
CC vs GC+GG: OR=1.10, 95% CI=0.9621.26,
Pheterpgeneity=0.441)(Table 2). When stratified according to
ethnicity, we found that rs2910164 polymorphism was associated
with increased BC risk among Europeans in homozygote
comparison (CC vs. GG: OR=1.29, 95%CI=1.0221.63,
Pheterpgeneity=0.950, P=0.032) (Figure. 2) and recessive model
(CC vs. GC+GG: OR=1.31, 95%CI=1.0521.65, Pheterpgene-
ity=0.839, P=0.019) (Figure. 3). However, only in recessive model
(CC vs. GC+GG: original P-value 0.019, Bonferroni P-value
0.076) remained associated to rs2910164 polymorphism and BC
risk among Europeans at a significance threshold of 0.1 after
Bonferroni correction.
Publication bias
Begg’s rank correlation method and Egger’s weighted regression
method were used to assess publication bias. No evidence of
publication bias was observed in any comparison model (GC
vs.GG: Begg’s test P=0.707, Egger’s test P=0.955; CC vs.GG:
Begg’s test P=0.452, Egger’s test P=0.130; GC+CC vs.GG:
Begg’s test P=0.707, Egger’s test P=0.976; CC vs.GC+GG:
Begg’s test P=0.707, Egger’s test P=0.078) (Figure. 4).
Discussion
The identification of single-nucleotide polymorphisms (SNPs)
that affect gene function or expression and contribute to BC
susceptibility is important to help predict individual and
population risk and understand the pathogenesis of BC. A G.C
polymorphism (rs2910164) has been identified in the gene for miR-
146a, a microRNA that binds to the 39 UTR of BRCA1 [15,16].
This G/C SNP (rs2910164) is located within the seed sequence of
pre-miR-146a, which is the miR-146a precursor. [16]. The
rs2910164 polymorphism has been associated with the risk of
papillary thyroid cancer [29], hepatocellular cancer [30], esoph-
ageal squamous cell cancer [31], gastric cancer [32,33], prostate
cancer [34,35] and glioma [36]. However, the relationship
between rs2910164 polymorphism and BC susceptibility is
undetermined. In 2008, shen et al. first reported a correlation
between rs2910164 polymorphism in miR-146a and early cancer
onset in familial BRCA1/BRCA2-negative breast/ovarian cancer
patients [16]. This finding was replicated in a study based on 101
familial BC cases negative for mutations in BRCA1/2 [19], but
not in a larger case-control study on 844 German and 760 Italian
Rs2910164 CC Associated with Breast Cancer Risk
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31615Table 1. Characteristics of the studies included in this meta-analysis.
First
author Year Country Ethnicity
Genotyping
methods
Sample size
(case/control) Case (%) Control (%) PHWE
GG GC CC GG GC CC
Hu 2008 China Asian PCR-RFLP 1009/1093 165(16.4) 515(51.0) 329(32.6) 180(16.5) 551(50.4) 362(33.1) 0.221
Hoffman 2009 USA Mix MassARRAY 439/478 234(53.3) 176(40.1) 29(6.6) 273(57.1) 178(37.2) 27(5.6) 0.775
Pastrello 2010 Italy European Sequencing 88/155 53(60.2) 30(34.1) 5(5.7) 90(58.1) 59(38.1) 6(3.9) 0.332
Catucci 2010 Italy European PCR-RFLP 754/1243 409(54.2) 286(37.9) 59(7.8) 650(52.3) 520(41.8) 73(5.9) 0.019
Catucci 2010 Germany European PCR-RFLP 805/904 451(56.0) 304(37.8) 50(6.2) 536(59.3) 318(35.2) 50(5.5) 0.753
Garcia 2011 France European Taqman 1130/596 676(59.8) 388(34.3) 66(5.8) 352(59.1) 220(36.9) 24(4.0) 0.150
PCR-RFLP: Polymerase Chain Reaction-restriction Fragment Length Polymorphism; HWE: Hardy-Weinberg Equilibrium.
doi:10.1371/journal.pone.0031615.t001
Figure 1. Flow chart of selection of studies and specific reasons for exclusion from the meta-analysis.
doi:10.1371/journal.pone.0031615.g001
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Moreover, Hu et al. failed to confirm the association of rs2910164
with BC risk in Chinese women [21]. Recently, Garcia et al.
showed that the rs2910164 SNP in the miR-146a gene was not
associated with BC risk in BRCA1 and BRCA2 mutation carriers
[18]. In this meta-analysis, we summarized current data on the
association between miR-146a rs2910164 polymorphism and BC
risk. We found that hsa-miR-146a rs2910164 G.C polymorphism
was associated with a significantly increased risk of BC in the CC
homozygote as opposed to the GG homozygote or GC/GG
genotype among Europeans. These findings suggest, for the first
time, that the CC homozygote of rs2910164 polymorphism may
contribute to BC susceptibility.
MicroRNAs could function as tumor suppressors or oncogenes
and are down-regulated or up-regulated in human tumors,
including BC. Based on array data, it was previously reported
that miR-146a was significantly upregulated in breast carcinoma
tissues compared with normal breast tissues [37]. Overexpression
of miR-146a has been reported as a signature in breast, pancreatic
and prostate cancers [37,38]. A unique example of a functional
miRNA SNP is rs2910164, which is located in the 3p strand of mir-
146a. This polymorphism involves a mispairing in the hairpin of
the precursor, which leads to altered processing, lower expression
of the mature sequence and predisposition to papillary thyroid
carcinoma [29]. However, differences in genotype distribution
have been found in a few case-control studies. Okubo et al. found
that the rs2910164 CC genotype was associated with a
significantly higher risk of gastric cancer when compared to
non-cancer subjects [32]. In contrast, male individuals with GG
genotype were 2-fold more susceptible to hepatocellular carcino-
ma (HCC) compared with those with CC genotype [30]. In
addition, Guo et al. reported that rs2910164 genotype GG was
associated with increased risk of esophageal squamous cell
carcinoma compared with variant genotype CC in a Chinese
Han population [31]. In this meta-analysis, significant association
was found between the rs2910164 CC genotype and BC risk in
Europeans. These results suggest that the molecular mechanisms
underlying the genetic associations of miRNA-SNPs (mir-SNPs)
with cancer are complex and the polymorphism might play a
different role in different cancers.
One important property of the gene polymorphism is that their
incidence can vary substantially between different racial or ethnic
populations. Xu et al. found significant differences in the
prevalence of the rs11614913 T allele and rs2910164 C allele
among controls of Asian (0.544 and 0.498, respectively) and
Caucasian (0.375 and 0.246, respectively) [39]. At population
Figure 2. Meta-analysis with a fixed-effects model for the association between breast cancer risk and the has-miR-146a rs2910164
polymorphism(CC vs GG) is illustrated in subgroup analysis by ethnicity. OR: odds ratio; CI: confidence interval; I
2, measure to quantify the
degree of heterogeneity in meta-analyses.
doi:10.1371/journal.pone.0031615.g002
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reduce cancer susceptibility in Asians but not in Caucasians,
suggesting a possible role of ethnic differences in the genetic
background and the environment they lived in (unpublished data).
Meta-analysis is a powerful statistical tool that provides a
consensus by combining the data from diverse studies that reveal
inconsistent results on the same problem. Some results of our study
did not show any statistical significance. However, subgroup
analysis by ethnicity showed a statistical significant result,
suggesting genetic diversity among different ethnicities.
Although many previous studies have been carried out to reveal
the potential associations between mir-SNPs and cancer risk, most
Figure 3. Meta-analysis with a fixed-effects model for the association between breast cancer risk and the has-miR-146a rs2910164
polymorphism (CC vs GC+GG) is illustrated in subgroup analysis by ethnicity. OR: odds ratio; CI: confidence interval; I
2, measure to quantify
the degree of heterogeneity in meta-analyses.
doi:10.1371/journal.pone.0031615.g003
Table 2. Quantitative analyses of has-miR-146a rs2910164 polymorphism on breast cancer risk.
Variables N
a GC versus GG CC versus GG GC/CC versus GG (dominant) CC versus GC/GG (recessive)
OR (95% CI) P
b OR (95% CI) P
b OR (95% CI) P
b OR (95% CI) P
b
Total 6 1.00 (0.90–1.09) 0.364 1.16 (0.98–1.36) 0.757 1.02 (0.93–1.12) 0.562 1.10 (0.96–1.26) 0.441
Ethnicities
European 4 0.96 (0.86–1.08) 0.263 1.29 (1.02–1.63) 0.950 1.00 (0.90–1.12) 0.427 1.31 (1.05–1.65) 0.839
Asian 1 1.02 (0.80–1.30) __ 0.99 (0.77–1.28) __ 1.00 (0.80–1.27) __ 0.98 (0.81–1.17) __
Mix 1 1.15 (0.88–1.51) __ 1.25 (0.72–2.18) __ 1.17 (0.90–1.51) __ 1.18 (0.69–2.03) __
The numbers in bold indicated statistically significant values.
aNumber of comparisons.
bP value of Q-test for heterogeneity test.
doi:10.1371/journal.pone.0031615.t002
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have not been included in current genome-wide association studies
(GWAS) designs [14]. The inclusion of mir-SNPs in future GWAS
will help to unveil low-penetrance susceptible mutations.
In interpreting the current results, some limitations should be
considered. First, lack of the original data of the reviewed studies
limited our further evaluation of potential interactions, because the
interactions between genes and between genes and environment
may modulate breast cancer risk. Second, only published studies
were included in this meta-analysis, unpublished data and ongoing
studies were not sought, which may have biased our results. Third,
all case-control studies were from Asia, Europe, and the United
States. Thus our results may be applicable only to these ethnic
groups. In spite of these, our meta-analysis has some advantages.
First, in the present study, no obvious heterogeneity between
studies was observed in overall comparisons by the Q-test. Second,
according our selection criteria, the quality of studies included in
our meta-analysis was satisfactory. Third, no publication bias was
detected, indicating that the whole pooled results may be
unbiased.
In conclusion, this meta-analysis suggests that CC genotype of
has-miR-146a rs2910164 polymorphism is associated with an
increased breast cancer risk in Europeans. Caution must be made
about the interpretation of the results because of the limited
sample size. Additional large case-control studies are necessary to
validate our findings, especially in non-Europeans.
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